ELV
$421.49-2.28%
as of close, Oct 27, 2026
☾ AH $421.49 -2.28%
ELV — Elevance Health Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
150.0200.0250.0300.0350.0400.0450.0500.0010.0M20.0M$421.49—20162019202120242026
2026-10-27
Price$421.49
MA20$402.99
MA50$360.73
Vol5.6M
Key stats#
Price data
- Price
- $421.49
- YTD price return
- +20.24%
- YTD total return
- +22.00%
- Market cap
- 91.1B
- Enterprise value
- 112.2B
- Shares outstanding
- 216.1M
- 52W low
- $274.84
- 52W high
- $450.69
- From 52W high
- -6.48%
- From 52W low
- +53.36%
- 52W range
- 83%
- Beta
- 0.68
Volume
- Rel volume
- 1.17×
- 30D volume
- 1.3M
- 30D $ vol
- 547.1M
Insider trading
- Insider net 1W
- −$4.7M
- Insider net 1M
- −$4.7M
- Insider net 3M
- −$4.7M
- Insider net 1Y
- −$4.2M
Form 4 transactions by trade date, as filed; latest on file 2026-10-22.
Fundamentals
- Sales (ttm)
- 201.8B
- Sales/share
- $934.16
- EPS (ttm)
- $23.43
- FCF (ttm)
- 6.5B
- FCF/share
- $30.15
- Book value/share
- $206.80
- Net margin
- 2.55%
- ROE
- 11.50%
- ROA
- 4.02%
- Debt / equity
- 0.68×
- Current ratio
- 1.47
Growth (CAGR, ttm) · 10Y
- Sales
- +3.60%+6.17%+8.56%+9.25%
- Net income
- -7.13%-5.01%-1.41%+8.46%
- FCF
- +72.99%-7.56%-7.23%+6.74%
- Shares
- -2.78%-2.76%-2.30%-1.96%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -3.95%-2.28%+1.01%+10.64%
- Sales/share
- +6.57%+9.18%+11.11%+11.44%
- FCF/share
- +77.94%-4.94%-5.05%+8.88%
- Book value/share
- +4.57%+8.14%+6.99%+8.21%
- Dividend/share
- +1.63%+6.30%+9.62%+10.31%
- Price
- +23.08%-1.53%-0.57%+13.00%
- Total return
- +25.53%+0.13%+0.90%+14.56%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 18.0×
- P/OI (ttm)
- 16.8×
- Fwd P/E
- 14.6×
- P/S (ttm)
- 0.5×
- P/B (mrq)
- 2.0×
- P/FCF (ttm)
- 14.0×
- EV/EBITDA (fy)
- 16.2×
- EV/Sales (ttm)
- 0.6×
- FCF yield (ttm)
- 7.15%
- Dividend yield (fwd)
- 1.63%
- Dividend yield (ttm)
- 1.63%
- Dividend/share (fwd)
- $6.88
- Buyback yield (realized, 1y)
- 2.78%
- Shareholder yield (realized, 1y)
- 4.87%
- Buyback yield (cash, ttm)
- 2.37%
- Shareholder yield (cash, ttm)
- 4.02%
Vs own 10Y history
- P/E
- 59th
- P/OI
- 97th
- P/S
- 14th
- P/B
- 28th
- P/FCF
- 42nd
Bar = where today’s multiple sits in ELV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-2.28%
5D
-4.25%
1M
+6.41%
3M
+11.40%
YTD
+20.24%
1Y
+23.07%
5Y
-2.81%
Recent filings#
- Oct 22Insider sale · Kaye Mark (EVP & CFO) sold 10,584 shares for $4.7M at $434.00–$447.19
- Oct 21Earnings · Earnings release — EPS $6.99 vs $4.66 est. (+50.0%); revenue $51.43B (+1% y/y) 1.4%
- Jul 17Insider buy · BOUDREAUX GAIL (President and CEO · Director) bought 2,725 shares for $1.0M at $366.41–$368.25
- Jul 17Insider buy · PERU RAMIRO G (Director) bought 1,000 shares for $366K at $366.05
- Jul 15Earnings · Earnings release — EPS $7.45 vs $6.18 est. (+20.6%); revenue $50.47B (+1% y/y) 8.5%
Financial statements
Open full ELV financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
